bioRxiv Science⌕ Search

Biology subjects

Odabas, A.

Publications and source records attributed to Odabas, A..

4 recordsLinked to original sources

KLF17 acts as a dual reporter for tracking naive pluripotency and 8-cell-like states

Human pluripotent stem cells (hPSCs) can be stabilized in states corresponding to successive stages of preimplantation development. Conventional primed hPSCs resemble the post-implantation epiblast, naive hPSCs the pre-implantation epiblast, and rare 8-cell-like cells (8CLCs) arising within naive cultures recapitulate features of zygotic genome activation (ZGA) at the 8-cell stage of early human embryonic development. To enable monitoring of these successive states, we exploited the expression of KLF17, which is absent from primed hPSCs and present in the human 8-cell embryo at levels exceeding those of the epiblast. We hypothesized that its expression level, rather than its presence alone, would report position along the continuum of early human development. We therefore generated an EGFP knock-in at the endogenous KLF17 locus and asked whether expression level could resolve two consecutive transitions in the same line. During conversion of primed cells to the naive state, KLF17-positive cells showed elevated expression of naive-associated genes including SUSD2, DNMT3L, DPPA3, DPPA5, TFCP2L1 and CD75 relative to the negative fraction, and formed blastoids at higher efficiency. Higher KLF17 levels in turn marked the naive-to-8C-like transition: following TSA and DZNep treatment, cells sorted into negative, low, mid and high fractions showed a progressive increase in ZGA-associated transcripts such as ZSCAN4, LEUTX, TPRX1, MBD3L2, DUXA and RFPL2. KLF17 expression level thus provides a single continuous readout of position along early human development, from the primed state through naive identity to the 8C-like state.

developmental biology↗

Rapid and efficient generation of human 8-cell-like cells for embryo modelling

8-cell blastomeres of human embryos possess broad lineage potential and undergo major zygotic genome activation (ZGA), yet experimental access to this transient cell state remains limited. Rare 8-cell-like cells (8CLCs) arise spontaneously in naive pluripotent stem cell cultures, but their low abundance has constrained mechanistic and functional studies. Here, we develop a chemically defined strategy for rapid and robust induction of 8CLCs. Through sequential small-molecule screens focused on chromatin regulators, we identify five compounds acting through distinct pathways that generate up to 40% 8CLCs within 48 hours. The resulting cells, which we term rapidly induced 8CLCs (ri8CLCs), recapitulate key molecular features of 8-cell blastomeres, including induction of ZGA-associated genes, cleavage-stage transposable elements, and 8-cell-stage transcriptional signatures in bulk and single-cell transcriptomic analyses. Functionally, ri8CLCs exhibit enhanced developmental competence, acquiring the ability for spontaneous extraembryonic differentiation and assembly into well-cavitated blastoids on an accelerated 72-hour timeline. Notably, ri8CLC induction enables blastoid formation even in the absence of MEK inhibition, TGF-{beta}/Activin/Nodal inhibition and exogenous LIF, revealing a developmental competence consistent with an early embryonic state. Together, these findings establish a rapid, defined, and highly efficient platform for generating human ri8CLCs and provide a tractable model for studying early human embryogenesis.

developmental biology↗

Single-gene knockout of RNLS or HIVEP2 are insufficient to protect β-cell spheroids from allo- and xeno-rejection

Type 1 diabetes can be cured by {beta}-cell replacement in principle, yet recurrent autoimmunity and transplantation barriers rapidly destroy implanted cells. Genome-wide CRISPR screening by Cai et al. highlighted RNLS and HIVEP2 as candidate genes, but their value outside an autoimmune setting is unknown. Here, it was evaluated whether single-gene knockout of RNLS or HIVEP2 could similarly protect {beta}-cell grafts against allo- and xenogeneic rejection. Murine {beta}-TC-6 and human EndoC-{beta}H1 cell lines were genetically edited using CRISPR-Cas9 to knockout RNLS or HIVEP2, and editing efficiencies were confirmed via T7 endonuclease I assay and TIDE analysis. Functional characterization indicated that RNLS deletion modestly impaired glucose-stimulated insulin secretion in murine cells, whereas HIVEP2 deletion showed no functional alterations in either cell line. For in vivo assessment, genetically edited {beta}-cell spheroids were subcutaneously transplanted into CD-1 mice to model allo- (murine {beta}-cells) and xenogeneic (human {beta}-cells) rejection scenarios. Bioluminescence imaging revealed no protective effects of RNLS or HIVEP2 deletion, with grafts from both knockout groups displaying identical rejection kinetics compared to controls. These findings indicate that single-gene deletions of RNLS or HIVEP2 are insufficient for conferring meaningful protection against allo- or xenorejection, highlighting the necessity for combinatorial genome editing strategies or complementary biomaterial-based immunomodulation to achieve effective and sustained {beta}-cell graft survival.

bioengineering↗

ACE2-Coated Virus-Like Particles Effectively Block SARS-CoV-2 Infection

A large body of research accumulated over the past three years dedicated to our understanding and fighting COVID-19. Blocking the interaction between SARS-CoV-2 Spike and ACE2 receptor has been considered an effective strategy as anti-SARS-CoV-2 therapeutics. In this study, we developed ACE2-coated virus-like particles (ACE2-VLPs), which can be utilized to prevent viral entry into host cells and efficiently neutralize the virus. These ACE2-VLPs exhibited high neutralization capacity even when applied at low doses, and displayed superior efficacy compared to extracellular vesicles carrying ACE2, in the in vitro pseudoviral assays. ACE2-VLPs were stable under different environmental temperatures, and they were effective in blocking all tested variants of concern in vitro. Finally, ACE2-VLPs displayed marked neutralization capacity against Omicron BA.1 in the Vero E6 cells. Based on their superior efficacy compared to extracellular vesicles, and their demonstrated success against live virus, ACE2-VLPs can be considered as vital candidates for treating SARS-CoV-2. This novel therapeutic approach of VLP coating with receptor particles can serve as proof-of-concept for designing effective neutralization strategies for other viral diseases in the future. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=78 SRC="FIGDIR/small/558424v1_ufig1.gif" ALT="Figure 1"> View larger version (16K): org.highwire.dtl.DTLVardef@30ac94org.highwire.dtl.DTLVardef@1926217org.highwire.dtl.DTLVardef@165d9f0org.highwire.dtl.DTLVardef@1c737f9_HPS_FORMAT_FIGEXP M_FIG In our study, we demonstrate the prevention of SARS-CoV-2 infection through the use of Ace2-coated VLPs. C_FIG

bioengineering↗